Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Chen Shwezin, Inc. dba Park Compounding Pharmacy
483
•Chen Shwezin, Inc. dba Park Compounding Pharmacy•April 3, 2018

Chen Shwezin, Inc. dba Park Compounding Pharmacy – FDA 483, Apr 3, 2018

Record Details

The FDA Form 483 inspection revealed significant deficiencies at the facility regarding drug product testing and equipment maintenance.

**Testing and Release:** The firm failed to conduct appropriate laboratory determination of identity and strength for each active ingredient prior to drug product release. Potency testing on three finished drug products over eight months did not adequately represent all distributed products or dosage forms, neglecting factors like production difficulty or active ingredient amount. Examples of products distributed without adequate assurance of meeting labeled strength claims include Lidocaine + Tetracaine 23+7% cream, Diclofenac suppository 100 mg, Trichloroacetic Acid 35% solution, Cantharidin Plus liquid, and Benzocaine + Lidocaine + Tetracaine 20+8+4% Lipoderm.

**Equipment and Utensil Maintenance:** Equipment and utensils were not cleaned, maintained, and sanitized at appropriate intervals. There were no written cleaning, sanitization, or maintenance procedures. Observed issues included: * Capsule plates designated clean contained powder residue. * Visible, loose powder on capsule machines. * An apparent hair stuck to residue on an ointment mill designated clean. * Spatulas used for product transfer had missing sections, creating rough surfaces. * Damaged powder containment hoods sealed with duct tape and packaging tape, showing powder residue on exposed adhesive. * Lack of documentation for cleaning process effectiveness in removing drug product residues and cleaning agents for encapsulation components

Company
Chen Shwezin, Inc. dba Park Compounding Pharmacy
Inspection date
April 3, 2018
Product type
Drugs
Office
Los Angeles District Office
Person
  • Nicholas L. Hunt (Senior CSO, Investigator)
View Company Profile

ID · 37fe8f2a-4c01-4dcf-858d-20684702f0c7

Violation Codes1
21 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Chen Shwezin, Inc. dba Park Compounding Pharmacy
  • STATE_REFERRAL_LETTER - 2018-03-26March 26, 2018
  • 483 - 2015-09-11September 11, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Chen Shwezin, Inc. dba Park Compounding Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.